Effect of Kanglaite Injection on Antiviral Activity of Entecavir in Patients with Hepatitis B-related Liver Cancer
Objective:To investigate the effect of Kanglaite Injection on the antiviral activity of Entecavir in patients with hepatitis B-related liver cancer.Method:A retrospective analysis of 119 patients with hepatitis B-related liver cancer in Central Hospital of Xinyu Iron and Steel Group Co.,LTD.from January 2020 to March 2022 was conducted.According to the treatment methods,they were divided into the combined treatment group(n=62)and the Entecavir group(n=57).The Entecavir group was treated with 0.5 mg Entecavir Capsules orally,and the combined treatment group was treated with Kanglaite Injection(intravenous drip 100 mL)on the basis of the Entecavir group.All patients were treated for 6 months.The efficacy,coagulation function indexes,liver function indexes and adverse reactions were compared between the two groups.Result:The total effective rate of the combined treatment group(87.10%)was higher than that(71.93%)of the Entecavir group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in coagulation function between the two groups(P>0.05).After treatment,the coagulation function indexes of both groups were improved,and the activated partial thrombin time(APTT),thrombin time(TT),prothrombin time(PT)and plasma fibrinogen(FIB)of the combined treatment group were lower than those of the Entecavir group,with statistical significance(P<0.05).Before treatment,there were no significant differences in liver function indexes between the two groups(P>0.05).After treatment,liver function indexes of both groups were improved,and the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),hepatitis B virus gene(HBV-DNA)and alpha-fetoprotein(AFP)in the combined treatment group were lower than those in the Entecavir group,the albumin(ALB)in the combined treatment group was higher than that in the Entecavir group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combined treatment group(27.42%)was higher than that(19.30%)in the Entecavir group,but the difference was not statistically significant(P>0.05).Conclusion:Kanglaite Injection combined with Entecavir can effectively treat patients with hepatitis B-related liver cancer,effectively inhibit HBV-DNA,and improve their blood function and liver function.
Kanglaite InjectionHepatitis BLiver cancerEntecavir
万方数据
维普
